{"id":"NCT02282930","sponsor":"Mayo Clinic","briefTitle":"Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","officialTitle":"An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03","primaryCompletion":"2018-06-30","completion":"2018-06-30","firstPosted":"2014-11-05","resultsPosted":"2019-06-26","lastUpdate":"2019-06-26"},"enrollment":20,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Progressive IgA Nephropathy","Proteinuria"],"interventions":[{"type":"DRUG","name":"ACTH (Acthar) Gel","otherNames":[]}],"arms":[{"label":"ACTH Gel","type":"EXPERIMENTAL"}],"summary":"This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in proteinuria and renal function.","primaryOutcome":{"measure":"Number of Subjects With a Complete or Partial Response to Treatment","timeFrame":"12 Months","effectByArm":[{"arm":"Acthar (ACTH) Gel","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Infection","Acne","Hot flashes","Soreness","Anxiety"]}}